Dulaglutide and Albiglutide are each a copy of the gut hormone GLP-1.
GLP-1 is what your gut releases after a meal to tell your brain you have eaten.
Same target, different schedules: Dulaglutide weekly; Albiglutide once weekly.
| Comparison | Dulaglutide (Trulicity) Trulicity · Dulaglutide | Albiglutide (Tanzeum) Tanzeum · Eperzan |
|---|---|---|
| How it works | How it works Dulaglutide copies GLP-1, a hormone your gut releases after eating. The trick is that it is stuck to a piece of an antibody, which stops your body clearing it for about a week. | How it works Albiglutide is worth a page mainly as a correction to the lists that still include it. |
| What it is | A weekly GLP-1 shot for diabetes, with far less weight loss than the famous ones. | A weekly GLP-1 withdrawn from the world market because nobody bought it. |
| Status | FDA approvedFDA-approved | FDA approvedFDA-approved (withdrawn) |
| Typical dose | 0.75–4.5 mg per week | — |
| How often | Weekly | Once weekly |
| Stays active | About 5 days | About 5 days |
| Dose comes from | FDA drug label | Discontinued programme |
| Cycled? | Taken continuously, with no planned break FDA drug label | Set by the prescription FDA drug label |
| What it does | ||
| Drug class | GLP-1 agonist | GLP-1 receptor agonist |
| Used for | A once-weekly injection for type 2 diabetes, taken to lower blood sugar. It also lowers the risk of heart problems. | A weekly injected GLP-1 for type 2 diabetes. Withdrawn from the market and no longer available. |
| Receptors hit | GLP-1 | GLP-1 |
| Numbers | ||
| Full dose line | 0.75 up to 4.5 mg per week (start low, increase slowly) | Was set by the label |
| Why that cycle | Blood sugar rises again when it stops, so it is treated as ongoing medication rather than a course. The label sets no end date. | This is a prescription drug. Duration and schedule are set by the label and the prescriber, not by a cycling convention. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | Not disclosed |
| Common vial | — | — |
| Before you start | ||
| Route | Under the skin (subcutaneous) | Under the skin (subcutaneous) |
| Do not use if | A personal or family history of medullary thyroid cancer Multiple Endocrine Neoplasia syndrome type 2, an inherited hormone condition Known allergy to dulaglutide Pregnancy, without talking to your doctor | Not applicable as a prescription, because the product has been withdrawn worldwide and is not available A personal or family history of medullary thyroid carcinoma, or MEN 2, which was a labelled contraindication for this drug class Anything sold under this name on the research market, which is of unverifiable origin and cannot be the withdrawn product Pregnancy or breastfeeding |
What separates them
Proof behind the dose. Dulaglutide has a dose taken straight off an FDA drug label. Albiglutide has a dose from a programme that was stopped.
What doesn't differ: They are both taken the same way (under the skin) and aimed at the same thing (blood sugar). Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
Dulaglutide (Trulicity)
- Stomach upset is common, especially in the first weeks.
- Carries a boxed warning about a rare thyroid cancer seen in rodents.
- Severe stomach pain that does not go away, which can signal pancreatitis
- A lump or swelling in the neck, trouble swallowing, or a hoarse voice
Albiglutide (Tanzeum)
- Withdrawn from the worldwide market and not available.
- Injection site reactions were more common with this agent than with others in its class.
- Not applicable as a prescription, because the product is not available
- If you hold material sold under this name, treat its identity as unverified rather than assuming it is the withdrawn drug
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.